Skip to main content

Table 1 Selected characteristics among breast cancer cases by hormone receptor status: SEER program, 1990–2001

From: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

 

ER+PR+

ER+PR-

ER-PR+

ER-PR-

 

(n = 98,463)

(n = 19,886)

(n = 4,896)

(n = 31,930)

Characteristics

n

Column %

Row %

n

Column %

Row %

n

Column %

Row %

n

Column %

Row %

Age at diagnosis, years

            

   30–39

4,903

5.0

49.5

885

4.5

8.9

569

11.6

5.7

3,558

11.1

35.9

   40–49

18,575

18.9

60.9

2,490

12.5

8.2

1,508

30.8

4.9

7,929

24.8

26.0

   50–59

21,807

22.1

61.4

4,464

22.5

12.5

1,161

23.7

3.3

8,094

25.4

22.8

   60–69

22,019

22.4

65.9

4,752

23.9

14.2

801

16.4

2.4

5,856

18.3

17.5

   70–79

20,667

21.0

68.2

4,662

23.4

15.4

584

11.9

1.9

4,401

13.8

14.5

   ≥80

10,492

10.6

67.7

2,633

13.2

17.0

273

5.6

1.8

2,092

6.6

13.5

Diagnosis year

            

   1990–1992

16,500

16.8

61.6

3,751

18.9

14.0

1,111

22.7

4.1

5,435

17.0

20.3

   1993–1995

22,087

22.4

61.7

4,514

22.7

12.6

1,485

30.3

4.1

7,728

24.2

21.6

   1996–1998

27,734

28.2

64.2

5,239

26.3

12.1

1,367

27.9

3.2

8,884

27.8

20.5

   1999–2001

32,142

32.6

65.2

6,382

32.1

12.9

933

19.1

1.9

9,883

31.0

20.0

SEER registry

            

   Atlanta, GA

5,696

5.8

59.4

1,171

5.9

12.2

381

7.8

4

2,344

7.3

24.4

   Connecticut

11,093

11.3

61.4

2,448

12.3

13.6

602

12.3

3.3

3,914

12.3

21.7

   Detroit, MI

10,559

10.7

60.4

2,314

11.6

13.2

539

11

3.1

4,063

12.7

23.3

   Hawaii

4,149

4.2

67.0

703

3.5

11.3

273

5.6

4.4

1,072

3.4

17.3

   Iowa

10,238

10.4

65.2

1,914

9.6

12.2

530

10.8

3.4

3,017

9.4

19.2

   Los Angeles, CA

15,586

15.8

61.4

3,399

17.1

13.4

919

18.8

3.6

5,491

17.2

21.6

   New Mexico

4,066

4.1

61.8

885

4.5

13.5

193

3.9

2.9

1,435

4.5

21.8

   San Francisco-Oakland, CA

13,063

13.3

63.9

2,750

13.8

13.5

652

13.3

3.2

3,957

12.4

19.4

   San Jose, CA

5,474

5.5

65.3

1,134

5.7

13.5

228

4.7

2.7

1,548

4.9

18.5

   Seattle, WA

14,241

14.5

68

2,517

12.7

12.0

423

8.6

2.0

3,770

11.8

18.0

   Utah

4,298

4.4

66.9

651

3.3

10.1

156

3.2

2.5

1,319

4.1

20.5

Race

            

   Non-Hispanic white

78,805

81.7

65.4

15,716

80.5

13.0

3,515

73.5

2.9

22,532

72.1

18.7

   African-American

5,724

5.9

48.0

1,488

7.6

12.5

504

10.5

4.2

4,206

13.5

35.3

   Native American

284

0.3

55.0

57

0.3

11.0

23

0.5

4.5

152

0.5

29.5

   Asian/Pacific Islander

6,065

6.3

65.1

1,061

5.4

11.4

382

8.0

4.1

1,805

5.8

19.4

   Hispanic white

5,585

5.8

57.8

1,203

6.2

12.4

359

7.5

3.7

2,524

8.1

26.1

   Other/Unknown

2,000

-

-

361

-

-

113

-

-

711

-

-

Tumor histology

            

   Ductal

71,199

72.3

62.7

13,981

70.3

12.3

3,641

74.4

3.2

24,722

77.4

21.8

   Lobular

8,980

9.1

73.6

2,160

10.9

17.7

283

5.8

2.3

784

2.5

6.4

   Ductal/Lobular

7,576

7.7

76.7

1,341

6.7

13.6

233

4.8

2.4

722

2.3

7.3

   Inflammatory

543

0.5

37.8

191

1.0

13.3

90

1.8

6.3

611

1.9

42.6

   Mucinous

2,927

3.0

80.9

486

2.4

13.5

41

0.8

1.1

164

0.5

4.5

   Tubular

1,696

1.7

79

327

1.6

15.2

44

0.9

2.1

79

0.3

3.7

   Comedo

1,159

1.2

43.6

318

1.6

12.0

179

3.6

6.7

1,003

3.1

37.7

   Medullary

266

0.3

14.7

148

0.8

8.2

97

2.0

5.4

1,292

4.0

71.7

   Papillary

582

0.6

79.0

58

0.3

7.9

10

0.2

1.3

87

0.3

11.8

   Other

3,535

3.6

49.4

876

4.4

12.2

278

5.7

3.9

2,466

7.7

34.5

Tumor stage

            

   I

50,172

52.4

69.2

9,232

48

12.7

1,999

42.7

2.8

11,114

36.2

15.3

   II

37,335

39.0

60.3

7,606

39.5

12.3

2,068

44.2

3.3

14,878

48.4

24.1

   III

5,332

5.5

51.3

1,471

7.6

14.1

385

8.2

3.7

3,210

10.4

30.9

   IV

2,943

3.1

52.1

936

4.9

16.6

230

4.9

4.1

1,536

5.0

27.2

   Unstaged

2,681

-

-

641

-

-

214

-

-

1,192

-

-

Tumor grade

            

   1

18,012

21.8

81.1

2,885

17.5

13.0

405

9.9

1.8

914

3.3

4.1

   2

40,642

49.3

74.2

7,133

43.4

13.0

1,324

32.5

2.4

5,682

20.6

10.4

   3

22,082

26.8

44.4

6,027

36.6

12.1

2,174

53.3

4.4

19,412

70.4

39.1

   4

1,774

2.1

45.0

413

2.5

10.5

173

4.3

4.4

1,579

5.7

40.1

   Unknown

15,953

-

 

3,428

-

 

820

-

 

4,343

-

 

Tumor size (cm)

            

   0–1.9

56,547

59.9

69.2

10,302

54.6

12.6

2,271

49.5

2.8

12,576

41.8

15.4

   2–5

32,977

34.9

58.7

7,135

37.8

12.7

1,891

41.3

3.4

14,147

47.1

25.2

   >5

4,949

5.2

48.8

1,432

7.6

14.1

422

9.2

4.2

3,330

11.1

32.9

   Unknown

3,990

-

-

1,017

-

-

312

-

-

1,877

-

-

Axillary lymph node status

            

   Negative

54,948

65.3

64.8

10,428

63.0

12.3

2,622

61.0

3.1

16,749

60.3

19.8

   Positive

29,234

34.7

60.9

6,110

37.0

12.7

1,675

39.0

3.5

11,015

39.7

22.9

   Unknown

14,281

-

-

3,348

-

-

599

-

-

4,166

-

-

Surgical treatment

            

   Performed

96,387

98.0

63.7

19,216

96.7

12.7

4,764

97.4

3.2

30,847

96.8

20.4

   Not performed

2,012

2.0

52.7

648

3.3

17.0

126

2.6

3.3

1,032

3.2

27

   Unknown

64

-

-

22

-

-

6

-

-

51

-

-

Radiation therapy

            

   Treated

46,859

48.5

65.5

8,694

44.5

12.1

2,048

42.9

2.9

13,922

44.8

19.5

   None

49,776

51.5

61.9

10,836

55.5

13.4

2,725

57.1

3.4

17,131

55.2

21.3

   Unknown

1,828

-

-

356

-

-

123

-

-

877

-

-

  1. ER, estrogen receptor; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us